Close Menu

Personal Genome Diagnostics

The firm expects to release an expanded liquid biopsy panel this year to help pharmaceutical partners perform blood-based biomarker discovery work. 

The firm will use the proceeds to expand its tissue and liquid biopsy product portfolio, as well as to fund future pharma and biotechnology partnerships.

Laboratories that purchase PGDx Elio genomic profiling tests will receive access to Qiagen's QCI Interpret One for rapid, evidence-based variant interpretation.

The nonexclusive deal includes Personal Genome Diagnostics' US Food and Drug Administration-cleared Elio Tissue Complete cancer genomic profiling assay.

News items for the in vitro diagnostics industry for the week of Sept. 7, 2020.

The firm said the FDA clearance was supported by data across several lab sites and all variant classes in clinical samples from 35 tumor types.

The partners will focus on optimizing technology and conducting clinical utility studies for liquid biopsy and tissue-based genomic applications.

A federal court said Guardant CEO Helmy Eltoukhy deleted emails pertaining to two similar cases, but it remains unclear whether he did so intentionally.

The company is using the test to direct patient enrollment and treatment stratification in a trial of pembrolizumab (Keytruda) combination treatments.

The in vitro diagnostic uses next-generation sequencing to detect clinically actionable genetic variants to guide therapy selection for cancer patients.

Pages